Skip to Content

Tate & Lyle PLC

TATE: XLON (GBR)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
GBX 415.00RskrnsWjvkdnl

Tate & Lyle Earnings: Makes Good Progress Improving EBITDA in Challenging Market Environment

Narrow moat Tate & Lyle reported first-half fiscal 2024 revenue of GBP 857 million and EBITDA of GBP 178 million, slightly above FactSet consensus that called for revenue and EBITDA of GBP 851 million and GBP 166 million, respectively. EBITDA was 7% higher in constant currency compared with the same period last year, driven by pricing actions, mix management, and cost savings. Management also shared their outlook for full-year fiscal 2024, expecting revenue slightly ahead of the prior year and EBITDA growth of 7% to 9%—in line with the year-to-date delivery and midterm guidance earlier this year. We do not expect to materially change our GBX 900 fair value estimate after incorporating these numbers. Shares are undervalued.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of TATE so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center